Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

When compared with the MMR II vaccine (M-M-R-II) currently available in the United States, a first dose of MMR-RIT (Priorix) given to 1-year-old children elicit

Source: Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
via
https://mailchi.mp/childrenshealthdefense.org/weekly-wrap-up-mmr-whistleblower-update-rfk-jr-is-moh-person-of-the-year-aluminum-warnings-ignored-falconry-with-rfk-jr-more?e=024df48761